Search Results - "MARGUS, B."

Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia by Veenhuis, S.J.G., Gupta, A.S., de Gusmão, C.M., Thornton, J., Margus, B., Rothblum-Oviatt, C., Otto, M., Halbgebauer, S., van Os, N.J.H., van de Warrenburg, B.P.C., Verbeek, M.M., Willemsen, M.A.A.P.

“…Neurofilament light chain (NfL) is recognized as a blood biomarker in several neurodegenerative disorders, but its possible relevance in Ataxia Telangiectasia…”
Get full text

Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis by GROSS, V., BAR‐MEIR, S., LAVY, A., MICKISCH, O., TULASSAY, Z., PRONAI, L., KUPCINSKAS, L., KIUDELIS, G., POKROTNIEKS, J., KOVÁCS, Á., FASZCZYK, M., RAZBADAUSKAS, A., MARGUS, B., STOLTE, M., MÜLLER, R., GREINWALD, R.

“…Summary Background  Rectal budesonide is an effective treatment of active ulcerative proctitis or proctosigmoiditis. Aim  To compare the therapeutic efficacy,…”
Get full text

Certolizumab Pegol for the Treatment of Crohn's Disease by Sandborn, William J, Feagan, Brian G, Stoinov, Simeon, Honiball, Pieter J, Rutgeerts, Paul, Mason, David, Bloomfield, Ralph, Schreiber, Stefan

“…In this randomized trial involving 662 patients with moderate-to-severe Crohn's disease, 23% of patients who were treated with certolizumab pegol (a pegylated…”
Get full text

Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks by Manns, M. P., Wedemeyer, H., Singer, A., Khomutjanskaja, N., Dienes, H. P., Roskams, T., Goldin, R., Hehnke, U., Inoue, H.

“…Chronic hepatitis C patients often fail to respond to interferon‐based therapies. This phase III study aimed at confirming the efficacy and safety of…”
Get full text

Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double‐blind, randomized, placebo‐controlled study by POKROTNIEKS, J, MARLICZ, K, PARADOWSKI, L, MARGUS, B, ZABOROWSKI, P, GREINWALD, R

“…Background: Rectal formulations of mesalazine are the treatment of choice in mildly to moderately active ulcerative colitis. A new foam formulation of…”
Get full text

Budesonide foam versus budesonide enema in active ulcerative proctitis and oroctosiqmoiditis by GROSS, V, BAR-MEIR, S, FASZCZYK, M, RAZBADAUSKAS, A, MARGUS, B, STOLTE, M, MÜLLER, R, GREINWALD, R, LAVY, A, MICKISCH, O, TULASSAY, Z, PRONAI, L, KUPCINSKAS, L, KIUDELIS, G, POKROTNIEKS, J, KOVACS, A

Get full text